Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit
February 23 2021 - 8:15AM
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical
company focused on the discovery, development and commercialization
of precision medicines for kidney diseases, today announced that
Andrew King, D.V.M., Ph.D., Head of Renal Discovery and
Translational Medicine, will present on behalf of Chinook at the
3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit.
Dr. King will deliver a presentation titled “Selective ETA receptor
antagonist atrasentan for the treatment of primary glomerular
diseases” on Thursday, March 4th at 10:00 am EST. Dr. King will
also participate in a panel discussion on executing precision
medicine in clinical trials on Wednesday, March 3rd at 2:45 pm EST.
The 3rd Annual CKD3 Summit is a unique virtual conference being
held March 2 – 4, 2021 that will bring together key opinion leaders
and stakeholders in kidney disease to identify and discuss topics
pertaining to drug development from discovery through regulatory
approval. For more information, please visit the CKD3 Summit
website located at https://ckd3-summit.com/.
About Chinook Therapeutics, Inc.Chinook
Therapeutics, Inc. is a clinical-stage biotechnology company
developing precision medicines for kidney diseases. Chinook’s
product candidates are being investigated in rare, severe chronic
kidney disorders with opportunities for well-defined clinical
pathways. Chinook’s lead program is atrasentan, an investigational
phase 3 endothelin receptor antagonist for the treatment of IgA
nephropathy and other primary glomerular diseases. BION-1301, an
investigational anti-APRIL monoclonal antibody is being evaluated
in a phase 1b trial for IgA nephropathy. In addition, Chinook is
advancing CHK-336, an investigational oral small molecule LDHA
inhibitor for the treatment of primary hyperoxaluria, as well as
research programs for other rare, severe chronic kidney diseases,
including polycystic kidney disease. Chinook is building its
pipeline by leveraging insights in kidney single cell RNA
sequencing, human-derived organoids and new translational models,
to discover and develop therapeutics with differentiating
mechanisms of action against key kidney disease pathways. To learn
more, visit www.chinooktx.com.
Contact:Noopur LiffickVice President, Investor
Relations & Corporate Communicationsinvestors@chinooktx.com
media@chinooktx.com
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From Apr 2024 to May 2024
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From May 2023 to May 2024